Impaired pharmacokinetics of levothyroxine in severely obese volunteers

Thyroid

Volumn 21, Issue 5, 2011, Pages 477-481

  Michalaki, Marina A ^a   Gkotsina, Margarita I ^a   Mamali, Irene ^a   Markantes, Georgios K ^a   Faltaka, Amalia ^a   Kalfarentzos, Fotios ^a   Vagenakis, Apostolos G ^a   Markou, Kostas B ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE SODIUM; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OBESITY; PLASMA VOLUME; PRIORITY JOURNAL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; AUTOANTIBODIES; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; OBESITY; THYROID HORMONES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 79957476797     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2010.0149     Document Type: Article

References (27)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM 2006 Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555.
2. Tsigos C, Hainer V, Basdevant A, Finer N, Fried M, Mathus- Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Zahorska-Markiewicz B 2008 Management of obesity in adults: European Clinical Practice Guidelines. Obes Facts 1:106-116.
3. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH 2006 Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113:898-918.
4. Xing J, Chen JD 2004 Alterations of gastrointestinal motility in obesity. Obes Res 12:1723-1732. (Pubitemid 41133019)
5. Hays MT 1991 Localization of human thyroxine absorption. Thyroid 1:241-248.
6. Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F 1995 Delayed intestinal absorption of levothyroxine. Thyroid 5:249-253.
7. Woeber K 2005 Treatment of hypothyroidism. In: Braverman LE, Utiger R (eds) Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 9th edition. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 864-869.
8. Toft AD 1994 Thyroxine therapy. N Engl J Med 331:174-180. (Pubitemid 24209569)
9. Liel Y, Harman-Boehm I, Shany S 1996 Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 81:857-859. (Pubitemid 26055713)
10. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH 1987 Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 316:764-770. (Pubitemid 17046084)
11. Peran S, Garriga MJ, Morreale de Escobar G, Asuncion M, Peran M 1997 Increase in plasma thyrotropin levels in hypothyroid patients during treatment due to a defect in the commercial preparation. J Clin Endocrinol Metab 82:3192-3195. (Pubitemid 27419055)
12. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G, Rago T, Mammoli C, Elisei R, Vitti P 2005 Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 90:124-127. (Pubitemid 40116644)
13. Lemmens HJ, Bernstein D, Brodsky J 2006 Estimating blood volume in obese and morbidly obese patients. Obes Surg 16:773-776. (Pubitemid 43874836)
14. Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE 2004 Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid 14:191-200. (Pubitemid 38452191)
15. Blakesley VA 2005 Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. AAPS J 7:E42-E46. (Pubitemid 41554301)
16. Scanlon M, Toft A 2000 Regulation of thyrotropin secretion In: Braverman LE, Utiger R (eds) Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 234-254.
17. FDA/CDER Inc: Approved Drug Products With Therapeutic Equivalence Evaluations, 23rd edition. 2003. Available at www.fda.gov/cder/ob/docs/preface/ ecpreface, accessed September 29, 2003.
18. Klotz U 1976 Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet 1:204-218.
19. Dunforth EJ, Horton ES, O?Connel M, Sims EA, Burger AG, Ingbar SH, Braverman L, Vagenakis AG 1979 Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest 64:1336-1347.
20. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE 2006 Thyroid function in humans with morbid obesity. Thyroid 16:73-78. (Pubitemid 43348719)
21. Reinehr T 2010 Obesity and thyroid function. Mol Cell Endocrinol 316:165-171
22. Michalaki M, Vagenakis AG, Makri M, Kalfarentzos F, Kyriazopoulou V 2001 Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 86:4198-4205. (Pubitemid 32848536)
23. Katzeff HL, Selgrad C 1993 Impaired peripheral thyroid hormone metabolism in genetic obesity. Endocrinology 132:989-995. (Pubitemid 23068610)
24. Pihlajamaki J, Boes T, Kim EY, Dearie F, Kim BW, Schroeder J, Mun E, Nasser I, Park PJ, Bianco AC, Goldfine AB, Patti ME 2009 Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab 94: 3521-3529.
25. Visser WE, Friesema EC, Jansen J, Visser TJ 2007 Thyroid hormone transport by monocarboxylate transporters. Best Pract Res Clin Endocrinol Metab 21:223-236. (Pubitemid 46888199)
26. Biondi B, Palmieri EA, Lombardi G, Fazio S 2002 Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 137:904-914. (Pubitemid 35416626)
27. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228-238. (Pubitemid 38082818)